NCT01526473View on ClinicalTrials.gov

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2017

Conditions
HER2+ Cancer
Interventions
BIOLOGICAL

AVX901

Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

lead

H. Kim Lyerly

OTHER

NCT01526473 - A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Biotech Hunter | Biotech Hunter